NASDAQ:OCGN
Ocugen (OCGN)
Financials 
Technical Analysis 
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free
- «
- ‹
- 1
- ›
- »
Ocugen (OCGN) Frequently Asked Questions
What is Ocugen stock symbol?
Ocugen is a American stock, trading under the symbol OCGN (previously OCGN-Q on Stockchase) on the NASDAQ (OCGN). It is usually referred to as NASDAQ:OCGN or OCGN
Is Ocugen a buy or a sell?
In the last year, there was no coverage of Ocugen published on Stockchase.
Is Ocugen a good investment or a top pick?
Ocugen was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Ocugen.
Why is Ocugen stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Ocugen worth watching?
In the last year, there was no coverage of Ocugen published on Stockchase.
What is Ocugen stock price?
On 2026-05-29, Ocugen (OCGN) stock closed at a price of $1.38.
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free